Determinants of linear growth faltering among children with moderate-to-severe diarrhea in the Global Enteric

Rebecca L Brander1, Patricia B Pavlinac2, Judd L Walson3

  • 1Department of Epidemiology, University of Washington, Seattle, WA, USA. rbrander@uw.edu.

BMC Medicine
|November 27, 2019
PubMed

Insights

Moderate-to-severe diarrhea (MSD) in young children can stunt growth. Factors like young age and malnutrition predict growth faltering, enabling early intervention for at-risk infants and toddlers.

Area of Science:

  • Pediatric Gastroenterology
  • Global Child Health
  • Nutritional Epidemiology

Background:

  • Moderate-to-severe diarrhea (MSD) in children under two years old is a significant risk factor for impaired linear growth.
  • Identifying children at high risk for growth faltering after MSD is crucial for timely intervention.

Purpose of the Study:

  • To identify clinical and sociodemographic risk factors for linear growth faltering in children with MSD.
  • To develop a clinical prediction tool for identifying children most vulnerable to growth deterioration post-MSD.

Main Methods:

  • Log-binomial and linear regression analyses were performed on data from the Global Enteric Multicenter Study (GEMS) involving 5902 children (0-23 months) with MSD in Africa and Asia.
  • A prediction model was developed using backward elimination and Akaike Information Criterion, incorporating factors like age, malnutrition, and clinical signs.

Main Results:

  • Severe linear growth faltering (loss of ≥0.5 length-for-age z-score) occurred in 24.2% of children over 50-90 days follow-up.
  • Younger age (0-12 months), acute malnutrition, non-dysenteric diarrhea, poor sanitation, and IMCI danger signs were associated with growth decline.
  • A prediction model including age, wasting, stunting, fever, and danger signs achieved an AUC of 0.67.

Conclusions:

  • Younger age, acute malnutrition, MSD severity, and sociodemographic factors significantly impact short-term linear growth after diarrhea.
  • Routine data collected during MSD episodes can effectively identify children at risk for growth deterioration, guiding targeted interventions.
Abstract

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
388
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
585
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
538
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
573
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
206
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
688